INT24889

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1989
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 36
Total Number 36
Disease Relevance 16.76
Pain Relevance 4.73

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleolus (CABIN1) nucleus (CABIN1) cytoplasm (CABIN1)
Anatomy Link Frequency
T cell 3
globus pallidus 2
kidney 2
brain 1
CABIN1 (Homo sapiens)
Pain Link Frequency Relevance Heat
headache 21 100.00 Very High Very High Very High
Enkephalin 16 99.92 Very High Very High Very High
corticosteroid 279 99.80 Very High Very High Very High
substance P 14 99.56 Very High Very High Very High
fibrosis 68 98.72 Very High Very High Very High
Inflammation 115 97.68 Very High Very High Very High
withdrawal 74 97.32 Very High Very High Very High
Neuropeptide 2 89.92 High High
cytokine 170 88.96 High High
Antihistamine 15 88.64 High High
Disease Link Frequency Relevance Heat
Headache 15 99.96 Very High Very High Very High
Renal Failure 216 99.92 Very High Very High Very High
Lichen Sclerosus Et Atrophicus 28 99.84 Very High Very High Very High
Striatonigral Degeneration 6 99.80 Very High Very High Very High
Organ Transplantation 54 99.40 Very High Very High Very High
Headache Disorders 2 99.34 Very High Very High Very High
Disease 156 99.06 Very High Very High Very High
Fibrosis 56 98.72 Very High Very High Very High
INFLAMMATION 115 97.68 Very High Very High Very High
Diabetes Mellitus 109 97.52 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In the cases with Huntington's disease (HD) and striatonigral degeneration (SND), marked loss of calcineurin, MEnk and SP-like immunoreactivities was seen in the globus pallidus corresponding to areas of striatal neurodegeneration, whereas synaptophysin immunoreactivity remained in areas which revealed almost complete loss of calcineurin, MEnk and SP-like immunoreactivities.
Negative_regulation (loss) of calcineurin in globus pallidus associated with striatonigral degeneration, enkephalin, disease and substance p
1) Confidence 0.48 Published 1989 Journal Acta Neuropathol. Section Abstract Doc Link 2479214 Disease Relevance 0.45 Pain Relevance 0.88
In the cases with Huntington's disease (HD) and striatonigral degeneration (SND), marked loss of calcineurin, MEnk and SP-like immunoreactivities was seen in the globus pallidus corresponding to areas of striatal neurodegeneration, whereas synaptophysin immunoreactivity remained in areas which revealed almost complete loss of calcineurin, MEnk and SP-like immunoreactivities.
Negative_regulation (loss) of calcineurin in globus pallidus associated with striatonigral degeneration, enkephalin, disease and substance p
2) Confidence 0.48 Published 1989 Journal Acta Neuropathol. Section Abstract Doc Link 2479214 Disease Relevance 0.47 Pain Relevance 0.90
Calcineurin inhibitor-induced headache: clinical characteristics and possible mechanisms.
Negative_regulation (inhibitor-induced) of Calcineurin associated with headache
3) Confidence 0.42 Published 2005 Journal Headache Section Title Doc Link 15836594 Disease Relevance 0.20 Pain Relevance 0.40
OBJECTIVE: To classify the headache syndromes under treatment with calcineurin inhibitors and to investigate whether the latter influence the nitric oxide production of human brain microvascular cells (HBMEC).
Negative_regulation (inhibitors) of calcineurin in brain associated with headache
4) Confidence 0.37 Published 2005 Journal Headache Section Abstract Doc Link 15836594 Disease Relevance 0.17 Pain Relevance 0.17
This complex of ciclosporin and cyclophilin inhibits calcineurin, which is responsible for activating the transcription of interleukin-2.
Negative_regulation (inhibits) of calcineurin
5) Confidence 0.28 Published 2009 Journal Clin Transplant Section Abstract Doc Link 19930311 Disease Relevance 0.27 Pain Relevance 0.15
Calcineurin inhibitor such as ciclosporin A inhibits T-cell activation by interfering with the cytosolic protein cyclophilin (immunophilin).
Negative_regulation (inhibitor) of Calcineurin in T-cell
6) Confidence 0.28 Published 2009 Journal Clin Transplant Section Abstract Doc Link 19930311 Disease Relevance 0.16 Pain Relevance 0.10
The introduction of calcineurin inhibitors was a landmark and acute rejection in organ transplantation decreased remarkably.
Negative_regulation (inhibitors) of calcineurin associated with organ transplantation
7) Confidence 0.24 Published 2009 Journal Clin Transplant Section Abstract Doc Link 19930311 Disease Relevance 0.15 Pain Relevance 0.09
This is important since most of the limiting side effects produced by these drugs arise via calcineurin inhibition.
Negative_regulation (inhibition) of calcineurin
8) Confidence 0.23 Published 2000 Journal Expert Opin Investig Drugs Section Abstract Doc Link 11060810 Disease Relevance 0.46 Pain Relevance 0.09
Furthermore, the neuroregenerative property does not involve calcineurin inhibition (essential for immunosuppression).
Negative_regulation (inhibition) of calcineurin
9) Confidence 0.20 Published 2000 Journal Expert Opin Investig Drugs Section Abstract Doc Link 11060810 Disease Relevance 0.48 Pain Relevance 0.10
Tacrolimus and cyclosporine, both calcineurin inhibitors, can cause neurological side effects.
Negative_regulation (inhibitors) of calcineurin
10) Confidence 0.17 Published 2006 Journal BMC Nephrol Section Abstract Doc Link PMC1440850 Disease Relevance 0.71 Pain Relevance 0
The efficacy of calcineurin inhibitors in LS are mainly due to their immunosuppressive and anti-inflammatory effects.
Negative_regulation (inhibitors) of calcineurin associated with inflammation and lichen sclerosus et atrophicus
11) Confidence 0.13 Published 2004 Journal BMC Dermatol Section Body Doc Link PMC526260 Disease Relevance 1.51 Pain Relevance 0.33
The authors concluded that use of belatacept in renal transplant recipients may enable calcineurin inhibitor and corticosteroid avoidance, with acceptable rates of acute rejection and improved glomerular filtration rate, although graft loss remains a concern.39
Negative_regulation (inhibitor) of calcineurin associated with corticosteroid and renal failure
12) Confidence 0.08 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2998809 Disease Relevance 0.50 Pain Relevance 0.08
As calcineurin inhibition underlies the immunosuppressive properties of these clinically used immunophilin ligands, this holds promise for the neuroprotective efficacy of nonimmunosuppressive analogs of FK506 in the prevention or treatment of antiretroviral toxic neuropathy.
Negative_regulation (inhibition) of calcineurin associated with neuropathic pain
13) Confidence 0.07 Published 2003 Journal Ann. Neurol. Section Abstract Doc Link 12509848 Disease Relevance 0.99 Pain Relevance 0.14
Patients 6–36 months post-transplantation (n = 173) with glomerular filtration rates of 35–75 mL/min were randomized to either belatacept 5 mg/kg (less intensive) or continued treatment with a calcineurin inhibitor.
Negative_regulation (inhibitor) of calcineurin
14) Confidence 0.07 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2998809 Disease Relevance 0.23 Pain Relevance 0
The odds of development of new-onset diabetes after transplantation were significantly lower (OR = 0.19, credible interval 0.08–0.42) with belatacept compared with both calcineurin inhibitors.
Negative_regulation (inhibitors) of calcineurin associated with diabetes mellitus
15) Confidence 0.07 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2998809 Disease Relevance 0.16 Pain Relevance 0
A number of novel drugs are currently under investigation in Phase I, II, or III clinical trials, primarily to replace the nephrotoxic but highly effective calcineurin inhibitors.
Negative_regulation (inhibitors) of calcineurin
16) Confidence 0.06 Published 2010 Journal Drug Design, Development and Therapy Section Abstract Doc Link PMC2998809 Disease Relevance 0.17 Pain Relevance 0
Multiple other trials, including the use of belatacept along with various agents like sirolimus and alemtuzumab, are currently in progress.46 Because tacrolimus has largely replaced cyclosporine as the calcineurin inhibitor of choice, trials comparing tacrolimus with belatacept would be crucial in confirming the results presented above.
Negative_regulation (inhibitor) of calcineurin
17) Confidence 0.06 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2998809 Disease Relevance 0.29 Pain Relevance 0
Ashman et al reported successful use of belatacept as maintenance immunosuppression in a young kidney transplant patient who developed de novo thrombotic microangiopathy serially in association with cyclosporine, tacrolimus, and sirolimus.47 A compassionate use study to make belatacept available for renal transplant recipients who are intolerant to or having contraindications to calcineurin inhibitors and/or mTOR inhibitors is currently enrolling patients.


Negative_regulation (inhibitors) of calcineurin in kidney associated with renal failure and thrombosis related under development
18) Confidence 0.06 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2998809 Disease Relevance 0.36 Pain Relevance 0
The stimulatory action of DAMGO was blocked by cyclosporine A (2 microM), an inhibitor of calcineurin, and was dependent on Ca2+ entry through nifedipine-sensitive Ca2+ channels.
Negative_regulation (inhibitor) of calcineurin
19) Confidence 0.04 Published 2006 Journal Life Sci. Section Abstract Doc Link 16460765 Disease Relevance 0.08 Pain Relevance 0.52
Furthermore we have shown that overexpression of regulator of calcineurin 1 isoform 4 (RCAN1-4)—a negative regulator of calcineurin signalling—leads to a reduction in PROK1 induced IL-11, indicating that RCAN1-4 is acting as a negative regulator in the signalling pathway mediating IL-11 expression.
Negative_regulation (regulator) of calcineurin
20) Confidence 0.03 Published 2010 Journal Molecular Human Reproduction Section Body Doc Link PMC2816169 Disease Relevance 0.06 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox